A bill to allow the sponsor of an application for the approval of a targeted drug to rely upon data and information with respect to such sponsor's previously approved targeted drugs.
The bill’s titles are written by its sponsor.
Sponsor and status
Sponsor. Senator for Colorado. Democrat.
Last Updated: Apr 5, 2016
Length: 10 pages
Sep 15, 2015
114th Congress, 2015–2017
Died in a previous Congress
This bill was introduced on February 9, 2016, in a previous session of Congress, but was not enacted.
What stakeholders are saying
Sep 15, 2015
Feb 9, 2016
A committee has voted to issue a report to the full chamber recommending that the bill be considered further. Only about 1 in 4 bills are reported out of committee.
S. 2030 (114th) was a bill in the United States Congress.
This bill was introduced in the 114th Congress, which met from Jan 6, 2015 to Jan 3, 2017. Legislation not enacted by the end of a Congress is cleared from the books.
How to cite this information.
Civic Impulse. (2018). S. 2030 — 114th Congress: Advancing Targeted Therapies for Rare Diseases Act of 2016. Retrieved from https://www.govtrack.us/congress/bills/114/s2030
“S. 2030 — 114th Congress: Advancing Targeted Therapies for Rare Diseases Act of 2016.” www.GovTrack.us. 2015. February 23, 2018 <https://www.govtrack.us/congress/bills/114/s2030>
|title=S. 2030 (114th)
|accessdate=February 23, 2018
|author=114th Congress (2015)
|date=September 15, 2015
|quote=Advancing Targeted Therapies for Rare Diseases Act of 2016